Dew
I want to catch up on the remarkable (or soon-to-be-remarkable) GTCB. I am going to take a position in this one, and besides, no-one here will discuss SCLN's prospects with me ..... ;o) ;o) .....so I will have to sell it.
A few questions: after checking out the "read-me-first page", I don't see where the EMEA trial actual results were discussed (I do see where there were 2 DVTs - was that the only end-point ?). Also, what is the historical rate of DVTs (or other endpoint events or occurrence) - meaning how does the "control arm" typically fare ?
In other words, is the efficacy compelling that the EMEA / FDA will have to put up with their queasiness about a mammalian rather than a mechanical manufacturing facility ?
TiA
ps: If the simple answer is to direct me to the GTCB website - then do so - I have to admit I have not trawled it yet.
News 
Market Data 
Discover 
